Skip to main content
. 2018 Nov 5;18:1065. doi: 10.1186/s12885-018-4974-5

Fig. 3.

Fig. 3

Diagnostic outcomes of serum miR-99a-5p for the prediction of EOC. a ROC analysis for miR-99a-5p (black line), CA125 (dotted line), and both miR-99a-5p and CA-125 together (red line) for the discrimination of patients with EOC (n = 62) from healthy volunteers (n = 20). b ROC analysis for miR-99a-5p (black line), CA125 (dotted line), and both miR-99a-5p and CA125 together (red line) for the discrimination of patients with early-stage EOC (n = 31) from healthy volunteers (n = 20). c ROC analysis for miR-99a-5p (black line), CA125 (dotted line), and both miR-99a-5p and CA125 together (red line) for the discrimination of patients with EOC (n = 62) from those with benign tumors (n = 26). Each AUC value is shown on the graph